Early trial tests new drug combos for tough blood cancers
NCT ID NCT03940352
Summary
This early-stage study tested two different drug combinations for adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), two serious blood and bone marrow cancers. The main goal was to find safe doses and see how well the combinations were tolerated. The trial was terminated early and involved 52 participants who had not responded well to previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center .
Durham, North Carolina, 27710, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Helsinki, FIN 00290, Finland
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Würzburg, 97080, Germany
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Madrid, 28041, Spain
Conditions
Explore the condition pages connected to this study.